JP2023517293A5 - - Google Patents

Info

Publication number
JP2023517293A5
JP2023517293A5 JP2022552793A JP2022552793A JP2023517293A5 JP 2023517293 A5 JP2023517293 A5 JP 2023517293A5 JP 2022552793 A JP2022552793 A JP 2022552793A JP 2022552793 A JP2022552793 A JP 2022552793A JP 2023517293 A5 JP2023517293 A5 JP 2023517293A5
Authority
JP
Japan
Prior art keywords
side chains
seq
bridged
amino acid
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517293A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/020940 external-priority patent/WO2021178714A2/en
Publication of JP2023517293A publication Critical patent/JP2023517293A/ja
Publication of JP2023517293A5 publication Critical patent/JP2023517293A5/ja
Pending legal-status Critical Current

Links

JP2022552793A 2020-03-04 2021-03-04 抗ウイルスの構造的に安定化されたＳＡＲＳ－ＣｏＶ－２ペプチドおよびその使用 Pending JP2023517293A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062985100P 2020-03-04 2020-03-04
US62/985,100 2020-03-04
PCT/US2021/020940 WO2021178714A2 (en) 2020-03-04 2021-03-04 ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2023517293A JP2023517293A (ja) 2023-04-25
JP2023517293A5 true JP2023517293A5 (enExample) 2024-09-12

Family

ID=75223491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552793A Pending JP2023517293A (ja) 2020-03-04 2021-03-04 抗ウイルスの構造的に安定化されたＳＡＲＳ－ＣｏＶ－２ペプチドおよびその使用

Country Status (8)

Country Link
US (1) US20240124529A1 (enExample)
EP (1) EP4114431A2 (enExample)
JP (1) JP2023517293A (enExample)
KR (1) KR20220148869A (enExample)
CN (1) CN115811984A (enExample)
AU (1) AU2021230544A1 (enExample)
CA (1) CA3173973A1 (enExample)
WO (1) WO2021178714A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297498A (en) * 2020-04-24 2022-12-01 Univ Columbia Lipid-peptide fusion inhibitors as sars-cov-2 antivirals
CN113817026B (zh) * 2021-09-16 2023-06-30 中国人民解放军海军军医大学 靶向刺突蛋白hr1的订书肽、制备方法及抗新型冠状病毒应用
CN113773370B (zh) * 2021-10-15 2022-07-22 哈尔滨吉象隆生物技术有限公司 一种抗病毒的多肽及其应用
CN118354791A (zh) * 2021-10-22 2024-07-16 威斯康星校友研究基金会 抑制导致新冠肺炎疾病的病毒sars-cov-2感染的肽
CN114437196A (zh) * 2022-02-16 2022-05-06 复旦大学 一种抑制SARS-CoV-2感染的蛋白及其用途
EP4611789A1 (en) * 2022-11-06 2025-09-10 Leyden Laboratories B.V. Sars-cov-2 binding polypeptide
EP4676938A2 (en) * 2023-03-08 2026-01-14 Dana-Farber Cancer Institute, Inc. Hendra virus and nipah virus surface glycoprotein peptides, conjugates, and uses thereof
WO2025235945A1 (en) * 2024-05-10 2025-11-13 Red Queen Therapeutics, Inc. Methods of treating viral infections using a fusion inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
PT1053019E (pt) 1998-01-07 2004-04-30 Debio Rech Pharma Sa Acrilatos de poli(etileno-glicol) heterobifuncional degradaveis e geles e conjugados derivados dos mesmos
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
ES2586387T3 (es) 2003-11-05 2016-10-14 Dana-Farber Cancer Institute, Inc. Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular
WO2005077103A2 (en) * 2004-02-12 2005-08-25 Regents Of The University Of Colorado Compositions and methods for modification and prevention of sars coronavirus infectivity
US7491489B2 (en) * 2004-11-22 2009-02-17 The University Of Hong Knog Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
WO2007005249A2 (en) * 2005-06-29 2007-01-11 Hyperbranch Medical Technology, Inc. Nanoparticles and dendritic-polymer-based hydrogels comprising them
US8592377B2 (en) 2007-03-28 2013-11-26 President And Fellows Of Harvard College Stitched polypeptides
CA2700925C (en) 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
EP2247606B1 (en) * 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections
WO2009137532A1 (en) * 2008-05-06 2009-11-12 New York Blood Center Antiviral cell penetrating peptides
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
US9175047B2 (en) * 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2010263056B2 (en) * 2009-06-18 2016-01-07 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
CN102939101A (zh) * 2010-01-26 2013-02-20 科罗拉多大学董事会，法人 用于通用疫苗的流感病毒组合物和方法
GB2473525B (en) * 2010-07-19 2011-07-27 Alexander P Fisher System and method for growing plants
EP3391898A3 (en) * 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
CN107022008B (zh) * 2016-01-30 2021-04-23 山西锦波生物医药股份有限公司 广谱地抑制人类冠状病毒感染的多肽及其应用
US20190048038A1 (en) 2016-02-23 2019-02-14 Dana-Farber Cancer Institute, Inc. Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting
WO2019136824A1 (zh) * 2018-01-15 2019-07-18 中国人民解放军军事科学院军事医学研究院 抑制MERS-CoV感染的多肽

Similar Documents

Publication Publication Date Title
JP2023517293A5 (enExample)
JP2025166834A5 (enExample)
FI92210C (fi) Menetelmä farmaseuttisesti käyttökelpoisten GRF-analogien valmistamiseksi
EP1320541B1 (en) Tgf-beta inhibitors and methods
JP2015512876A5 (enExample)
CA2370289A1 (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
WO2000005260A1 (en) Peptide analogues of pacap
JPS62259598A (ja) 線維芽細胞発育因子きつ抗物質
HUT73494A (en) Analogs of peptide yy and uses thereof
ATE350049T1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
WO1997031019B1 (en) Antipathogenic peptides and compositions comprising them
JPH0291098A (ja) 生長ホルモン放出因子ペプチド
JPH0269499A (ja) 環状ｇｒｆ類似体
WO2019136824A1 (zh) 抑制MERS-CoV感染的多肽
JP2023116739A5 (enExample)
JP2025172140A5 (enExample)
JP2006523709A5 (enExample)
Rossevatn et al. The complete amino acid sequence of bovine serum amyloid protein a (saa) and of subspecies of the tissue‐deposited amyloid fibril protein a
US5252718A (en) Fibroblast growth factor antagonists
FI81589C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara grf-peptidanaloger.
EP0350318A2 (en) Novel peptides
US3864481A (en) Anti disease producing synthetic material for the prevention suppression and diagnosis of multiple sclerosis and method of treatment therefor
WO1993003766A1 (en) Multiple antigen peptides for use as hiv vaccines
CN1041157A (zh) 肽醇抗血凝剂
CN1030917A (zh) 免疫抑制肽